Long-term survival of patients with Burkitt's lymphoma: an assessment of treatment and other factors which may relate to survival.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality*; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007223:Infant; D007630:Kenya; D008297:Male; D008353:Mannitol / Q000627:therapeutic use; D008558:Melphalan / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D009603:Nitroso Compounds / Q000627:therapeutic use; D014508:Urea / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D009603:Nitroso Compounds; D003561:Cytarabine; D002699:Chlorambucil; D008353:Mannitol; D003520:Cyclophosphamide; D014508:Urea; D002066:Busulfan; D008558:Melphalan; D008727:Methotrexate